Suppr超能文献

补充铁剂的低出生体重儿红细胞超氧化物歧化酶活性降低。

Reduced erythrocyte superoxide dismutase activity in low birth weight infants given iron supplements.

作者信息

Barclay S M, Aggett P J, Lloyd D J, Duffty P

机构信息

Department of Child Health, University of Aberdeen, Scotland, United Kingdom.

出版信息

Pediatr Res. 1991 Mar;29(3):297-301. doi: 10.1203/00006450-199103000-00015.

Abstract

Erythrocyte superoxide dismutase (ESOD) activity reflects copper utilization and the risk of copper deficiency. To investigate the possible effects of inorganic iron on the metabolism of copper in low birth weight infants, we have measured ESOD activities in three groups of infants receiving different iron supplements. Fifty-five low birth weight infants were randomly assigned to receive daily from 28 d either 13.8 mg (HiFe), 7 mg (MidFe), or no elemental iron (NatFe) as iron edetate. At 27 d, 8, 12, and 20 wk postnatal age, infants were weighed and measured and hematologic indices, plasma ferritin, zinc, and copper concentrations, and ESOD activities were assayed. Anthropometrical and hematologic indices and plasma copper and zinc concentrations did not differ among treatment groups at any time, but at 20 wk, plasma ferritin concentrations [(micrograms/L) mean; SD] were lower in the NatFe group (17; 2.0) than in the HiFe group (32; 1.9: 95% confidence interval for mean difference 6.6 to 22.0, p less than 0.01). ESOD activities (U/g Hb) were similar in HiFe (1447; 263), MidFe (1552; 322), and NatFe (1538; 382) groups at 27 d, but by 20 wk activities in the HiFe group (1537; 211) were lower than in the MidFe (1789; 403: 95% confidence interval 38 to 466, p less than 0.05) and NatFe (1858; 304: 95% confidence interval 150 to 492, p less than 0.01) groups. The lower ESOD activities found in the HiFe group at 20 wk may reflect altered copper metabolism induced by the iron supplement, but the clinical importance of this observation is unknown.

摘要

红细胞超氧化物歧化酶(ESOD)活性反映了铜的利用情况以及铜缺乏的风险。为了研究无机铁对低体重儿铜代谢的可能影响,我们测量了三组接受不同铁补充剂的婴儿的ESOD活性。55名低体重儿被随机分配,从出生28天起每天分别接受13.8毫克(高剂量铁组,HiFe)、7毫克(中剂量铁组,MidFe)或不接受元素铁(自然铁组,NatFe)的依地酸铁。在出生后27天、8周、12周和20周时,对婴儿进行称重、测量,并检测血液学指标、血浆铁蛋白、锌和铜浓度以及ESOD活性。在任何时间,各治疗组之间的人体测量学和血液学指标以及血浆铜和锌浓度均无差异,但在20周时,自然铁组的血浆铁蛋白浓度[(微克/升)均值;标准差](17;2.0)低于高剂量铁组(32;1.9:均值差异的95%置信区间为6.6至22.0,p<0.01)。在27天时,高剂量铁组(1447;263)、中剂量铁组(1552;322)和自然铁组(1538;382)的ESOD活性(单位/克血红蛋白)相似,但到20周时,高剂量铁组(1537;211)的活性低于中剂量铁组(1789;403:95%置信区间为38至466,p<0.05)和自然铁组(1858;304:95%置信区间为150至492,p<0.01)。在20周时高剂量铁组中较低的ESOD活性可能反映了铁补充剂引起的铜代谢改变,但这一观察结果的临床重要性尚不清楚。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验